Kaigen Of Japan Plans 10 Percent Increase In Sales Staff
This article was originally published in PharmAsia News
Executive Summary
Japan's Kaigen plans a 10 percent annual increase in its sales staff to cover more institutions for two of its primary medical products. The firm said an X-ray barium contrast agent and its Alloid G treatment for peptic ulcer and reflex account for a large percentage of its sales. Alloid G alone accounts for about 30 percent, Kaigen said, and it hopes to double those sales within the next three years. The firm said part of its failure to cover all institutions in the country was its new business selling sterilizing devices and other medical equipment. (Click here for more - a subscription may be required
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.